Effects of selective cytochrome P-450 inhibitors on the metabolism of thioridazine. In vitro studies

Polish Journal of Pharmacology

Volumn 51, Issue 5, 1999, Pages 435-442

  Daniel, Władysława A ^a   Syrek, Maciej ^a   Haduch, Anna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

naphthoflavone; Cytochrome P 450 inhibition; Erythromycin; Metyrapone; Quinine; Rat; Sulfaphenazole; Thioridazine metabolism

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 INHIBITOR; ERYTHROMYCIN; METYRAPONE; QUININE; SULFAPHENAZOLE; THIORIDAZINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR; THIORIDAZINE;

EID: 0032756170     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Axelsson R.: On the serum concentrations and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine side-chain sulfone in chronic psychotic patients. Curr. Ther. Res., 1977, 21, 587-605.
2. Baldwin S. J., Bloomer J. C., Smith G. J., Ayrton A. D., Clarke S. E., Chenery R. J.: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 1995, 25, 261-270.
3. Baumann P., Meyer J. W., AmeyM., Baettig D., Bryois C., Jonzier-Perey M., Koeb L., Monney C., Woggon B.: Dextrometorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther. Drug Monit., 1992, 14, 1-8.
4. Blake B. L., Rose R. L., Mailman R. B., Levi P. E., Hodgson E.: Metabolism of thioridazine by microsomal monooxygenases: relative roles of P-450 and flavin-containing monooxygenase. Xenobiotica, 1995, 25, 377-393.
5. Bylund D. B.: Interactions of neuroleptic metabolites with dopaminergic, alpha-adrenergic and muscarinic cholinergic receptors. J. Pharmacol. Exp. Ther., 1981, 217, 81-86.
6. Cashman J. R., Yang Z., Yang L., Wrighton S.: Stereo-and regioselective N-and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes. Drug Metab. Disposition, 1993, 21, 492-501.
7. Daniel W.: Metabolism of psychotropic drugs: pharmacological and clinical relevance. Pol. J. Pharmacol., 1995, 47, 367-379.
8. Daniel W. A., Syrek M., Haduch A., Wójcikowski J.: The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. Exp. Toxicol. Pathol., 1999, 51, 309-314.
9. Daniel W. A., Syrek M., Mach A., Wójcikowski J., Boksa J.: Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment. Pol. J. Pharmacol., 1997, 49, 439-452.
10. i. Biochem. J., 1972, 129, 197-202.
11. Ealing V. A., Tjia I. F., Back D. J.: Differential selectivity of cytochrome P-450 inhibitors against probe substrates in human and rat liver microsomes. Brit. J. Clin. Pharmacol., 1998, 45, 107-114.
12. Ghosal A., Satoh H., Thomas P., Bush E., Moore D.: Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab. Disposition, 1996, 24, 940-947.
13. Gottschalk L. A., Dinovo E., Biener R., Nandi B. R.: Plasma concentrations of thioridazine metabolites and ECG abnormalities. J. Pharm. Sci., 1978, 67, 155-157.
14. Hale P. W. Jr., Poklis A.: Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol. Appl. Pharmacol., 1986, 86, 44-55.
15. Hyttel J., Larsen J. J., Christensen A. V., Amt J.: Receptor binding profiles of neuroleptics. In: Dyskinesia -Research and Treatment. Eds. Casey D. E., Chase T. N., Christensen A. V., Gerlach J., Springer, Berlin-Heidelberg, 1985, 9-18.
16. Kobayashi S., Murray S., Watson D., Sesardic D., Davies D. S., Boobis A. R.: The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem. Pharmacol., 1989, 38, 2795-2799.
17. Lin G., Hawes E. M., McKay G., Korchinski E. D., Midha K. K.: Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat. Xenobiotica, 1993, 23, 1059-1074.
18. Meyer J. W., Woggon B., Baumann P., Meyer U. A.: Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur. J. Clin. Pharmacol., 1990, 39, 613-614.
19. Murray M., Reidy G. F.: Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev., 1990, 42, 85-101.
20. Okey A. B.: Enzyme induction in the cytochrome P450 system. Pharmacol. Ther., 1990, 45, 241-298.
21. Papadopoulos A. S., Crammer J. L., Cowan D. A.: Phenolic metabolites of thioridazine in man. Xenobiotica, 1985, 15, 309-316.
22. Parmar D., Dhawan A., Seth P. K.: Evidence for O-dealkylation of 7-pentoxyresorufin by cytochrome P450 2B1/2B2 isoenzymes in brain. Mol. Cell. Biochem., 1998, 189, 201-205.
23. Richelson E., Nelson A.: Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur. J. Pharmacol., 1984, 103, 197-204.
24. Steiner E., Dumond E., Spina E., Dahlqvist R.: Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin. Pharmacol. Ther., 1988, 43, 577-581.
25. Svendsen C. N., Bird E. D.: HPLC with electrochemical detection to measure chlorpromazine, thioridazine and metabolites in human brain. Psychopharmacology, 1986, 90, 316-321.
26. Valoti M., Frosini M., Palmi M., De Matteis F., Sgaragli G.: N-dealkylation of chlorimipramine and chlorpromazine by rat liver microsomal cytochrome P450 isoenzymes. J. Pharm. Pharmacol., 1998, 50, 1005-1011.
27. von Bahr C., Movin G., Nordin C., Liden A., Hammarlund-Udenaes M., Hedberg A., Ring H., Sjögvist F.: Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther., 1991, 49, 234-240.
28. von Bahr C., Spina E., Birgersson C., Ericsson O., Goransson M., Henthorn T.: Inhibition of desmethyl-imipramine 2-hydroxylation by drugs in human liver microsomes. Biochem. Pharmacol., 1985, 34, 2501-2505.
29. Wrighton S. A., Stevens J. C.: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol., 1992, 22, 1-21.
30. Zehnder K., Kalberer F., Kreis W., Rutschmann J.: The metabolism of thioridazine (Melleril) and one of its pyrrolidine analogues in the rat. Biochem. Pharmacol., 1962, 11, 535-550.
31. Zhi-Guang T., Murray B., Sesardic D., Kobayashi S., Murray S., Davies D. S., Boobis A. R.: Quinidine discriminates between rat and human debrisoquine 4-hydroxylase. Brit. J. Clin. Pharmacol., 1988, 25, 674P.